Actemra [prescribing information]. South San Francisco, CA: Genentech, Inc.; December 2022.
Adakveo [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2021.
Aduhelm [prescribing information]. Cambridge, MA: Biogen; February 2023.
Aldurazyme [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc.; December 2019.
American Academy of Allergy, Asthma and Immunology. Guidelines for the Site of Care for Administration of IGIV Therapy. December 2011.
Amondys 45 [package insert]. Cambridge, MA: Sarepta Therapeutics; February 2021.
Amvuttra [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; February 2023.
Aralast NP [package insert]. Lexington, MA: Baxalta US Inc.; December 2018.
Asceniv [prescribing information.] Kankakee, IL: CSL Behring LLC; April 2019.
Avsola [prescribing information]. Thousand Oaks, CA: Amgen Inc.; September 2021.
Bavencio [prescribing information]. Rockland, MA: EMD Serono, Inc; July 2022.
Benlysta [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2022.
Bivigam [prescribing information]. Boca Raton, FL: Biotest Pharmaceuticals Corporation; December 2022.
Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238-1239.
Briumvi [prescribing information]. Morrisville, NC: TG Therapeutics, Inc.; December 2022.
Cerezyme [prescribing information]. Cambridge, MA: Genzyme Corporation.; December 2021.
Cinqair [prescribing information]. Frazer, PA: Teva Respiratory, LLC; February 2020.
Cinryze [prescribing information]. Lexington, MA: Shire ViroPharma Biologics Inc.; February 2023.
Crysvita [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc; June 2020.
Cutaquig [package insert]. Hoboken, NJ: Octapharma USA Inc; November 2021.
Cuvitru [package insert]. Lexington, MA: Baxalta USA Inc.; March 2023.
Elaprase [prescribing information]. Lexington, MA: Shire Human Genetic Therapies, Inc.; September 2021.
Elelyso [prescribing information]. NY, NY: Pfizer Inc.; August 2022.
Elfabrio [prescribing information]. Cary, NC: Chiesi USA, Inc.; May 2022.
Enjaymo [package insert]. Waltham, MA: Bioverativ USA Inc Inc.; March 2023.
Entyvio [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2022.
Evkeeza [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; February 2021.
Exondys 51 [prescribing information]. Cambridge, MA: Sarepta Therapeutics, Inc.; January 2022.
Fabrazyme [prescribing information]. Cambridge, MA: Genzyme Corporation.; March 2021.
Fasenra [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2021.
Flebogamma 10% DIF [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; November 2019.
Flebogamma 5% DIF [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; November 2019.
Gammagard Liquid [prescribing information]. Lexington, MA: Baxalta US Inc; March 2021.
Gammagard S/D IgA less than 1 mcg/mL [package insert]. Lexington, MA: Baxalta US Inc; March 2021.
Gammaked [package insert]. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2020.
Gammaplex 5% [package insert]. Durham, NC: Bio Products Laboratory Inc; November 2021.
Gammaplex 10% [package insert]. Durham, NC: Bio Products Laboratory Inc; November 2021.
Gamunex-C [package insert]. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2020.
Givlaari [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals.; January 2022.
Glassia [package insert]. Lexington, MA: Baxter US Inc.; March 2022.
Hemgenix [package insert]. King of Prussia, PA: CSL Behring LLC; November 2022.
Hizentra [package insert]. Kankakee, IL: CSL Behring LLC; April 2023.
HyQvia [package insert]. Lexington, MA: Baxalta USA Inc.; March 2021.
Imfinzi [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2022.
Inflectra [prescribing information]. Lake Forest, IL: Celltrion, Inc.; April 2023.
Jemperli [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; February 2023.
Kanuma [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals Inc.; November 2021.
Katzberg H, Rasutis V, Bril V Home iVIG for CIDP: A Focus on Patient Centred Care Can J Neurol Sci. 2013; 40: 384-388.
Keytruda [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; April 2023.
Lamzede [prescribing information]. Cary, NC: Chiesi USA, Inc.; February 2022.
Lemtrada [prescribing information]. Cambridge, MA: Genzyme Corp.; January 2023.
Leqembi [prescribing information]. Nutley, NJ: Eisai Inc.; January 2023.
Libtayo [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; April 2023.
Lumizyme [prescribing information]. Cambridge, MA: Genzyme Corporation; May 2022.
Luxturna [prescribing information]. Philadelphia, PA: Spark Therapeutics, Inc.; December 2019.
MCG Care Guidelines, 19th Edition, 2015, Home Infusion Therapy: CMT: CMT-0009
Mepsevii [prescribing information]. Novato, CA: Ultragenyx Pharmaceutical Inc.; December 2020.
Naglazyme [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc; December 2019.
Nexviazyme [prescribing information]. Cambridge, MA: Genzyme Corporation; August 2021.
Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline, Inc.; January 2022.
Ocrevus [prescribing information]. Genentech, Inc. South San Francisco, CA.; March 2023.
Octagam 10% [package insert]. Hoboken, NJ: Octapharma USA, Inc.; March 2022.
Octagam 5% [package insert]. Hoboken, NJ: Octapharma USA, Inc.; April 2022.
Onpattro (patisiran) [prescribing Information]. Alnylam Pharmaceuticals, Inc. January 2023.
Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2023.
Opdualag [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March 2022.
Orencia [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; December 2021.
Oxlumo [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; October 2022.
Panzyga [package insert]. Lingolsheim, France : Octapharma SAS, Inc; February 2021.
Privigen [package insert]. Bern, Switzerland: CSL Behring AG; March 2022.
Prolastin-C [package insert]. Research Triangle Park, NC: Grifols Therapeutics Inc.; May 2020.
Qalsody [package insert]. Cambridge, MA: Biogen Inc.; April 2023.
Radicava [prescribing information]. Jersey City, NJ: MT Pharma America, Inc.; May 2022.
Remicade [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; October 2021.
Renflexis [prescribing information]. Kenilworth, NJ: Merck & Co., Inc.; January 2022.
Rigas M, Tandan R, Sterling R. Safety of Liquid Intravenous Immunoglobulin for Neuroimmunologic Disorders in the Home Setting: A Retrospective Analysis of 1085 Infusions. J Clin Neuromusc Dis 2008; 10:52-55
Saphnelo [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2022.
Scheinman SJ and Drezner MK. Hereditary hypophosphatemic rickets and tumor-induced osteomalacia. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed September 2017.
Simponi Aria [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; February 2021.
Skysona [package insert]. Somerville, MA: Bluebird bio.; September 2022.
Soliris [prescribing information]. New Haven, CT: Alexion Pharmaceuticals Inc; November 2020.
Souayah N, Hasan A, Khan H, et. al. The Safety Profile of Home Infusion of Intravenous Immunoglobulin in Patients with Neuroimmunologic Disorders. J Clin Neuromusc Dis 2011; 12:S1-S10
Spinraza [package insert]. Cambridge, MA: Biogen Inc.; February 2023.
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171-178.
Tecentriq [prescribing information]. South San Francisco, CA: Genentech, Inc.; May 2023.
Tepezza [package insert]. Dublin, Ireland: Horizon Therapeutics Ireland DAC; December 2022.
Tezspire [package insert]. Thousand Oaks, CA: Amgen; February 2023.
Tysabri [prescribing information]. Cambridge, MA: Biogen Idec Inc.; April 2023.
U.S. Food and Drug Administration (FDA). FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia. Silver Spring, MD: FDA; April 21, 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604810.htm. Accessed April 24, 2018.
Ultomiris [prescribing information]. Boston, MA: Alexion Pharmaceuticals. Inc. July 2022.
Uplizna [prescribing information]. Gaithersburg, MD: Viela Bio, Inc.; July 2021.
Viltepso [prescribing information]. Paramus, NJ: NS Pharma, Inc.; March 2021.
Vimizim [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc; December 2019.
Vpriv [prescribing information]. Lexington, MA: Shire Human Genetic Therapies Inc; September 2021.
Vyondys 53 [prescribing information]. Cambridge, MA: Sarepta Therapeutics, Inc. February 2021.
Vyepti [package insert]. Bothell, WA: Lundbeck Seattle Bio Pharmaceuticals, Inc; October 2022.
Xembify [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
Xolair [package insert]. South San Francisco, CA: Genentech, Inc.; July 2021.
Yervoy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company. February 2023.
Zemaira [package insert]. Kankakee, IL: CSL Behring LLC.; September 2022.
Zolgensma [prescribing information]. Bannockburn, IL: AveXis, Inc.; February 2023.
Zynteglo [package insert]. Somerville, MA: Bluebird bio; August 2022.
Zynyz [package insert]. Wilmington, DE: Incyte Corporation; March 2023.